Varaico: Literature-Extracted Genetic Variants

Gene:GLA
Variant:p.E66G
Back to variants list

GLA

NM_000169.3:p.E66G

Associated Papers

Impact of GLA Variant Classification on the Estimated Prevalence of Fabry Disease: A Systematic Review and Meta-Analysis of Screening Studies.

Monda E et al.

Circulation. Genomic and Precision Medicine, 2023

38047356 (PubMed )
Supplement: circgenetics_circcvg-2023-004252-t_supp1.pdf

Fabry Disease in Slovakia: How the Situation Has Changed over 20 Years of Treatment.

Jurickova K et al.

Journal of Personalized Medicine, 2022

Challenging the traditional approach for interpreting genetic variants: Lessons from Fabry disease.

Germain DP et al.

Clinical Genetics, 2022

A Comparative Effectiveness Study of Newborn Screening Methods for Four Lysosomal Storage Disorders.

Sanders KA et al.

International Journal of Neonatal Screening, 2020

Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients.

Germain DP et al.

Clinical Genetics, 2019

Challenging popular tools for the annotation of genetic variations with a real case, pathogenic mutations of lysosomal alpha-galactosidase.

Cimmaruta C et al.

Bmc Bioinformatics, 2018

30497360 (PubMed )
Supplement: 12859_2018_2416_MOESM1_ESM.xlsx › ST1

The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.

Benjamin ER et al.

Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2017

27657681 (PubMed )
Supplement: gim2016122x1.zip › Supplemental_Appendix_2_12152015.xlsx › Non-Classic

The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations.

Citro V et al.

International Journal of Molecular Sciences, 2016

27916943 (PubMed )
Supplement: ijms-17-02010-s001.zip › ijms-157565-supplementary_file_1_done.xlsx › Tabella_aggiornamento

Comparative study of structural changes caused by different substitutions at the same residue on α-galactosidase A.

Saito S et al.

Plos One, 2013

Pharmacological chaperone therapy for Fabry disease.

Ishii S

Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 2012

High incidence of later-onset fabry disease revealed by newborn screening.

Spada M et al.

American Journal of Human Genetics, 2006

Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."